Literature DB >> 10092825

Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes.

Y Liu1, J M Cousin, J Hughes, J Van Damme, J R Seckl, C Haslett, I Dransfield, J Savill, A G Rossi.   

Abstract

Phagocyte recognition, uptake, and nonphlogistic degradation of neutrophils and other leukocytes undergoing apoptosis promote the resolution of inflammation. This study assessed the effects of anti-inflammatory glucocorticoids on this leukocyte clearance mechanism. Pretreatment of "semimature" 5-day human monocyte-derived macrophages (M phi) for 24 h with methylprednisolone, dexamethasone, and hydrocortisone, but not the nonglucocorticoid steroids aldosterone, estradiol, and progesterone, potentiated phagocytosis of apoptotic neutrophils. These effects were specific in that the potentiated phagocytosis of apoptotic neutrophils was completely blocked by the glucocorticoid receptor antagonist RU38486, and glucocorticoids did not promote 5-day M phi ingestion of opsonized erythrocytes. Similar glucocorticoid-mediated potentiation was observed with 5-day M phi uptake of alternative apoptotic "targets" (eosinophils and Jurkat T cells) and in uptake of apoptotic neutrophils by alternative phagocytes (human glomerular mesangial cells and murine M phi elicited into the peritoneum or derived from bone marrow). Importantly, methylprednisolone-mediated enhancement of the uptake of apoptotic neutrophils did not trigger the release of the chemokines IL-8 and monocyte chemoattractant protein-1. Furthermore, longer-term potentiation by methylprednisolone was observed in maturing human monocyte-derived M phi, with greater increases in 5-day M phi uptake of apoptotic cells being observed the earlier glucocorticoids were added during monocyte maturation into M phi. We conclude that potentiation of nonphlogistic clearance of apoptotic leukocytes by phagocytes is a hitherto unrecognized property of glucocorticoids that has potential implications for therapies aimed at promoting the resolution of inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092825

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  90 in total

1.  21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties.

Authors:  M Paul-Clark; P Del Soldato; S Fiorucci; R J Flower; M Perretti
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  The effect of dexamethasone on the generation of plasma DNA from dead and dying cells.

Authors:  Ning Jiang; David S Pisetsky
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 3.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

4.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes.

Authors:  Jan M Schwab; Nan Chiang; Makoto Arita; Charles N Serhan
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

Review 5.  Macrophage activation by endogenous danger signals.

Authors:  X Zhang; D M Mosser
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 6.  Biology of the TAM receptors.

Authors:  Greg Lemke
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

Review 7.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

8.  The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of Mcl-1L in neutrophils but not in eosinophils.

Authors:  Kelly L Sivertson; Michael C Seeds; David L Long; Kristina K Peachman; David A Bass
Journal:  Cell Immunol       Date:  2007-06-14       Impact factor: 4.868

9.  Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model.

Authors:  Michael G Gravett; Kristina M Adams; Drew W Sadowsky; Alexandra R Grosvenor; Steven S Witkin; Michael K Axthelm; Miles J Novy
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

Review 10.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.